This was never going to happen at a premium that line of thinking or questioning has to stop imo (particularly for a biotech seeking production for a not yet proven or FDA approved product). Negotiation is a two way street... and a 7% discount is actually quite substantial imo. The blaster will be well positioned for successor or failure at the behest of recent investors in the short term...
Ann: Trading Halt, page-729
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.78 |
Change
0.255(16.7%) |
Mkt cap ! $2.032B | |||
| Open | High | Low | Value | Volume |
| $1.74 | $1.83 | $1.71 | $27.76M | 15.59M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 30000 | $1.78 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.79 | 48074 | 4 |
View Market Depth
| Last trade - 16.10pm 14/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |